New research suggests the incidence of cardiac amyloidosis in the U.S. is trending up, bringing with it high rates of morbidity and mortality.

Just weeks after it fast-tracked dapagliflozin for the treatment of chronic kidney disease, the FDA announced it was granting Fast Track status to the drug for another indication: heart failure.

Research presented at the ESC Congress in Paris Sept. 2 suggests malaria could be linked to as much as a 30% increased risk of heart failure.

Research out of the Netherlands suggests current clinical guidelines might recommend overtreatment for women with heart failure, who see maximum benefit from HF drugs at half the dose of men.

SGLT2 inhibitors—namely dapagliflozin—have been linked to a reduced risk of heart failure and death, as well as decreased odds of major adverse cardiovascular events.

Oregon Health & Science University will resume its heart transplant services this month after nearly a year of inactivity, the university announced Aug. 26.

Managing new-onset HF is a delicate task for cardiologists, and one that demands an appropriate balance between aggressive treatment and optimal quality of life for the patient. But that balance may be harder to strike than previously thought, researchers reported in Circulation this month.

Istaroxime, a dual action, luso-inotropic agent that’s still in clinical development, was granted fast-track designation by the FDA this month as a possible treatment for HFrEF.